Gregory A. Otterson, MD, on Adjuvant Therapy and Immunotherapy for Lung Cancer
2015 NCCN Annual Conference
Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.
John A. Thompson, MD
John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the latest immunotherapeutics for advanced melanoma, including pembrolizumab, trametinib, nivolumab, and dabrafenib.
Ingrid A. Mayer, MD
Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.
Melinda Telli, MD
Melinda Telli, MD, of Stanford Cancer Institute, discusses the TNT trial for triple-negative breast cancer and the results reported at the San Antonio Breast Cancer Symposium.
Peter E. Clark, MD
Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.
Axel Grothey, MD
Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.